Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study | Zendy

Yuhong Dai | Zendy; Li Sun | Zendy; Liang Zhuang | Zendy; Mingsheng Zhang | Zendy; Yanmei Zou | Zendy; Xianglin Yuan | Zendy; Hong Qiu | Zendy

Open Access

Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study

Author(s) -

Yuhong Dai,

Li Sun,

Liang Zhuang,

Mingsheng Zhang,

Yanmei Zou,

Xianglin Yuan,

Hong Qiu

Publication year - 2022

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo-22-285

Subject(s) - medicine , apatinib , regorafenib , refractory (planetary science) , retrospective cohort study , colorectal cancer , oncology , cohort , safety profile , cancer , adverse effect , physics , astrobiology

At present, regorafenib and fruquintinib are the standard regimens for refractory metastatic colorectal cancer patients in China, but both options have limited efficacy. The aim of this study was to investigate the efficacy and safety of low-dose apatinib plus S-1 compared with regorafenib and fruquintinib in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research